ArticleCurrent microbiology2025
Nitroxoline Shows Synergy with Colistin Potentiating its Bactericidal Efficacy in Opportunist Pathogen Pseudomonas aeruginosa.
Article in Current microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Nitroxoline revisited: antibacterial mechanisms, spectrum, and therapeutic potential of an old drug in the era of antimicrobial resistance.Biochemical Society transactions · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pseudomonas aeruginosa is a highly virulent Gram-negative pathogen that exhibits multiple mechanisms of antibiotic resistance, including resistance to colistin, a last-resort therapeutic agent, posing a significant clinical challenge. Recently designated by the World Health Organization (WHO) as a high-priority pathogen, P. aeruginosa underscores the urgent need for novel therapeutic strategies. In this study, we explored the potential of combination therapy, specifically investigating the synergistic interaction between colistin and nitroxoline, a hydroxyquinoline derivative, against a highly colistin-resistant P. aeruginosa strain.Bacterial viability was assessed through growth curve analysis, and the mechanistic basis of the observed synergy was examined using membrane permeability assays, intracellular reactive oxygen species (ROS) quantification, and gene expression profiling via quantitative real-time PCR (qRT-PCR). Additionally, the impact of this combination on bacterial survival was evaluated by analyzing its effects on biofilm formation and persister cell development under antimicrobial stress, both critical contributors to chronic and treatment-refractory infections in humans.Our results demonstrate that nitroxoline potentiates the bactericidal activity of colistin by enhancing membrane permeability, leading to significant inhibition of planktonic growth and pronounced efficacy against structured microbial communities such as biofilms and persister cells. Furthermore, the combination therapy completely suppressed bacterial motility, a critical virulence trait that facilitates immune evasion.These findings present a compelling therapeutic strategy to combat antibiotic resistance in Gram-negative pathogens, including both wild-type and drug-resistant clinical isolates of P. aeruginosa and Acinetobacter baumannii. The study highlights the significant potential of the colistin-nitroxoline combination to mitigate colistin resistance and reduce the global burden of multidrug-resistant infections.
Indexed as
Identifiers
41171349What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.